A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung CancerTaofeek K. Owonikoko, Fadlo R. Khuri, Sungjin Kim et al.|Clinical Cancer Research|2015Cited by 26
Survival Analysis of Patients With Stage I Non–Small-Cell Lung Cancer Using Clinical and DNA Repair Pathway Expression VariablesMadhusmita Behera, Suresh S. Ramalingam, John Heine et al.|Clinical Lung Cancer|2012Cited by 4
Abstract LB-194: Window of opportunity preoperative interrogation of mTOR pathway in patients with resectable non-small cell lung cancer (NSCLC).Taofeek K. Owonikoko, Fadlo R. Khuri, Daniel Miller et al.|Cancer Research|2013Cited by 0
Data from A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung CancerTaofeek K. Owonikoko, Fadlo R. Khuri, Suresh S. Ramalingam et al.|Unknown|2023Cited by 0
Supplementary Table S1 from A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung CancerTaofeek K. Owonikoko, Fadlo R. Khuri, Suresh S. Ramalingam et al.|Unknown|2023Cited by 0